<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Psychiatry</journal-id><journal-id journal-id-type="pmc">IJPsy</journal-id><journal-title-group><journal-title>Indian Journal of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0019-5545</issn><issn pub-type="epub">1998-3794</issn><publisher><publisher-name>Medknow Publications</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21455398</article-id><article-id pub-id-type="pmc">2963000</article-id><article-id pub-id-type="publisher-id">IJPsy-41-249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>MULTICENTRIC EFFICACY STUDY OF CENTPROPAZINE AND IMIPRAMINE IN DEPRESSED PATIENTS</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Srivastava</surname><given-names>J.S.</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Asthana</surname><given-names>O.P.</given-names></name><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Singh</surname><given-names>H.</given-names></name><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Agarwal</surname><given-names>A.K.</given-names></name><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>L.P.</given-names></name><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>K.C.</given-names></name><xref ref-type="aff" rid="aff6"/></contrib><contrib contrib-type="author"><name><surname>Gopinath</surname><given-names>P.S.</given-names></name><xref ref-type="aff" rid="aff7"/></contrib><contrib contrib-type="author"><name><surname>Srimal</surname><given-names>R.C.</given-names></name><xref ref-type="aff" rid="aff8"/></contrib></contrib-group><aff id="aff1"><label>*</label>J.S. SRIVASTAVA, MD., DM., Division of Clinical &#x00026; Experimental Medicine, Central Drug Research Institute, Lucknow.</aff><aff id="aff2">O.P. ASTHANA, MD., DCH., Division of Clinical &#x00026; Experimental Medicine, Central Drug Research Institute, Lucknow.</aff><aff id="aff3">R.C. SRIMAL, MD.MD. Division of Clinical &#x00026; Experimental Medicine. Central Drug Research Institute, Lucknow</aff><aff id="aff4">H. SINGH, MD., Department of Psychiatry, K. G. Medical College, Lucknow.</aff><aff id="aff5">A.K. AGARWAL, MD., DPM., Department of Psychiatry, Seth G. S. Medical College, Mumbai.</aff><aff id="aff6">L.P. SHAH, MD., DPM., FRC Psych., Department of Psychiatry, Govt. Medical College, Patiala.</aff><aff id="aff7">K.C. SHARMA, MD., Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore.</aff><aff id="aff8">P.S. GOPINATH, MD., MD.Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore</aff><author-notes><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Division of Clinical &#x00026; Experimental Medicine. Central Drug Research Institute, Chattar Manzil Palace, Post Box No. 173 Lucknow-226 001. CDRI Communication No 5855.</corresp></author-notes><pub-date pub-type="ppub"><season>Jul-Sep</season><year>1999</year></pub-date><volume>41</volume><issue>3</issue><fpage>249</fpage><lpage>253</lpage><permissions><copyright-statement>Copyright: &#x000a9; Indian Journal of Psychiatry</copyright-statement><copyright-year>1999</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Centpropazine is a new antidepressant with minimal anticholinergic effects in preclinical animal models. In this study centpropazine has been compared with imipramine in a double blind randomized multicentric study. A total of 159 patients of major depressive disorder (79 in centpropazine group and 80 in imipramine group) from four centres were included in this trial. Each patient was randomised to receive either centpropazine in a dose of 40 to 120 mg per day or imipramine in a dose of 50 to 150 mg per day for a period of six weeks. The antidepressant efficacy of centpropazine was comparable to imipramine but anticholinergic side effects were four times less than imipramine. This establishes centpropazine as an effective antidepressant with remarkably safer tolerability profile.</p></abstract><kwd-group><kwd>Centpropazine antidepressants depression</kwd></kwd-group></article-meta></front></article>